Jung Hyun Her

2PUBLICATIONS
14CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

Sort by Publication Date:
|Mar 29, 2022
Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.

Jung Hyun Her, Dominik Pretscher, Maria Patra-Kneuer

|May 31, 2021
Adjuvant therapy using ex vivo-expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study.

Jong Man Kim, Sung Yoo Cho, Jinsoo Rhu

Pageof 1

Frequent Collaborators

2 joint publications

Sung Yoo Cho

2 joint publications

Yu-Kyeong Hwang

1 joint publications

Jong Man Kim

1 joint publications

Jinsoo Rhu

1 joint publications

Miyoung Jung

1 joint publications

Okjae Lim

1 joint publications

Gyu-Seong Choi

1 joint publications

Eui-Cheol Shin

1 joint publications

Jae-Won Joh

1 joint publications

Dominik Pretscher

Frequent Collaborators

2 joint publications

Sung Yoo Cho

2 joint publications

Yu-Kyeong Hwang

1 joint publications

Jong Man Kim

1 joint publications

Jinsoo Rhu

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on : May 22, 2020

3.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on : May 24, 2024

746
See more related videos

Top Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on : May 22, 2020

3.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on : May 24, 2024

746
See more related videos